Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed NYSE Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 55.34B 50.88B 47.88B 89.74B 6,017B 90.77B 605B 235B 2,950B 239B 234B 10,219B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 70.39B 64.71B 60.9B 114B 7,652B 115B 769B 299B 3,751B 304B 297B 12,997B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
24-10-18	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
24-08-27	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
24-06-27	Allergan Aesthetics Debuts Alle Payment Plans	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Stock

Stocks

AGN

IE00BY9D5467

Pharmaceuticals

Valuation: Allergan plc

Latest news : Allergan plc

Press Releases: Allergan plc

News in other languages: Allergan plc

Managers and Directors: Allergan plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	2016-11-30
Robert Michael PSD	President	55	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Date	Insider	Type	Main position	Quantity	% Market Cap.
20-05-07	James D'Arecca	Issuer sale	Controller/Auditor	19,495	0.0059%
20-05-07	Peter John McDonnell	Issuer sale	Director	6,352	0.0019%
20-05-07	Christopher Bodine	Issuer sale	Director	18,615	0.0057%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	-0.94%	-2.85%	+37.70%	+148.38%	1,001B
JOHNSON & JOHNSON	-0.42%	-1.18%	+50.88%	+42.60%	566B
ABBVIE INC.	-0.56%	-1.86%	+15.91%	+59.57%	393B
ROCHE HOLDING AG	-1.18%	+2.29%	+24.04%	+16.53%	326B
NOVARTIS AG	+1.09%	+2.21%	+25.56%	+33.32%	276B
ASTRAZENECA PLC	+1.42%	-1.17%	+24.53%	+14.29%	277B
NOVO NORDISK A/S	+1.87%	+5.96%	-42.67%	-48.26%	193B
AMGEN INC.	-1.78%	-0.84%	+15.60%	+48.77%	188B
GILEAD SCIENCES, INC.	-1.40%	-0.04%	+13.19%	+59.08%	158B
Average	+0.11%	+0.49%	+18.30%	+41.59%	344.05B
Weighted average by Cap.	-0.22%	-0.37%	+27.02%	+66.27%

	2018	2019
Net sales	15.79B 13.72B 12.62B 11.88B 22.25B 1,492B 22.51B 150B 58.22B 732B 59.25B 57.98B 2,534B	16.09B 13.99B 12.86B 12.1B 22.68B 1,521B 22.94B 153B 59.34B 745B 60.38B 59.09B 2,583B
Net income	-5.1B -4.43B -4.07B -3.83B -7.18B -482B -7.27B -48.41B -18.8B -236B -19.13B -18.72B -818B	-5.27B -4.58B -4.21B -3.96B -7.43B -498B -7.52B -50.07B -19.44B -244B -19.78B -19.36B -846B
Net Debt	21.89B 19.03B 17.5B 16.47B 30.86B 2,069B 31.21B 208B 80.73B 1,014B 82.15B 80.4B 3,514B	17.3B 15.04B 13.83B 13.02B 24.39B 1,636B 24.67B 164B 63.82B 802B 64.94B 63.55B 2,778B